Orchestra BioMed
OBIO
59 hedge funds and large institutions have $47.6M invested in Orchestra BioMed in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 19 closing their positions.
16% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 19
5% more funds holding
Funds holding: 56 → 59 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.63% less ownership
Funds ownership: 49.97% → 47.33% (-2.6%)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
41% less capital invested
Capital invested by funds: $81.3M → $47.6M (-$33.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$1.33M |
| 2 |
Millennium Management
New York
|
+$1.2M |
| 3 |
Renaissance Technologies
New York
|
+$494K |
| 4 |
DMKJ
David M. Knott Jr
|
+$292K |
| 5 |
RI
RTW Investments
New York
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.69M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$856K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$439K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$404K |
OBIO Hedge Fund Activity: Q2 2025 in Review
59 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2025, worth a combined $47.6M — down 41% from $81.3M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new OBIO positions and 19 closed out — a net gain of 3 holders — while 14 added to existing stakes and 16 trimmed.
The largest buyer was Knoll Capital Management, opening a new position worth an estimated $1.33M. The largest seller was BlackRock, cutting an estimated $3.69M.
- 59 institutional investors held Orchestra BioMed (OBIO) as of Q2 2025, up from 56 in Q1 2025.
- Funds reported $47.6M of Orchestra BioMed stock for Q2 2025, down 41% quarter-over-quarter.
- 22 funds opened new Orchestra BioMed positions in Q2 2025 and 19 closed out, a net change of +3 holders.
- The largest Orchestra BioMed buyer in Q2 2025 was Knoll Capital Management, an estimated $1.33M added.
- The largest Orchestra BioMed seller in Q2 2025 was BlackRock, an estimated $3.69M sold.
Based on aggregated 13F filings for Q2 2025.